Literature DB >> 23607482

Immune response to Streptococcus pneumoniae in asthma patients: comparison between stable situation and exacerbation.

C Otero1, R D Paz, N Galassi, L Bezrodnik, M R Finiasz, S Fink.   

Abstract

In Argentina, more than 3 million people suffer from asthma, with numbers rising. When asthma patients acquire viral infections which, in turn, trigger the asthmatic response, they may develop subsequent bacterial infections, mainly by Streptococcus (S.) pneumoniae. This encapsulated Gram(+) bacterium has been considered historically a T cell-independent antigen. Nevertheless, several papers describe the role of T cells in the immune response to S. pneumoniae. We evaluated the response to S. pneumoniae and compared it to the response to Mycobacterium (M.) tuberculosis, a different type of bacterium that requires a T helper type 1 (Th1) response, in cells from atopic asthmatic children, to compare parameters for the same individual under exacerbation and in a stable situation whenever possible. We studied asthma patients and a control group of age-matched children, evaluating cell populations, activation markers and cytokine production by flow cytometry, and cytokine concentration in serum and cell culture supernatants by enzyme-linked immunosorbent assay (ELISA). No differences were observed in γδ T cells for the same patient in either situation, and a tendency to lower percentages of CD4(+) CD25(hi) T cells was observed under stability. A significantly lower production of tumour necrosis factor (TNF)-α and a significantly higher production of interleukin (IL)-5 was observed in asthma patients compared to healthy individuals, but no differences could be observed for IL-4, IL-13 or IL-10. A greater early activation response against M. tuberculosis, compared to S. pneumoniae, was observed in the asthmatic patients' cells. This may contribute to explaining why these patients frequently acquire infections caused by the latter bacterium and not the former.
© 2013 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23607482      PMCID: PMC3694539          DOI: 10.1111/cei.12082

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

Review 1.  The innate immune response to pneumococcal lung infection: the untold story.

Authors:  Aras Kadioglu; Peter W Andrew
Journal:  Trends Immunol       Date:  2004-03       Impact factor: 16.687

2.  Cutting edge: antibody production to pneumococcal polysaccharides requires CD1 molecules and CD8+ T cells.

Authors:  Lisa J Kobrynski; Alexandra O Sousa; André J Nahmias; Francis K Lee
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

3.  Induction of phagocyte-stimulating and Th1-promoting cytokines by in vitro stimulation of human peripheral blood mononuclear cells with Streptococcus pneumoniae.

Authors:  E Arvå; B Andersson
Journal:  Scand J Immunol       Date:  1999-04       Impact factor: 3.487

4.  Asthma as a risk factor for invasive pneumococcal disease.

Authors:  Thomas R Talbot; Tina V Hartert; Ed Mitchel; Natasha B Halasa; Patrick G Arbogast; Katherine A Poehling; William Schaffner; Allen S Craig; Marie R Griffin
Journal:  N Engl J Med       Date:  2005-05-19       Impact factor: 91.245

5.  Increased interleukin-4, interleukin-5, and interferon-gamma in airway CD4+ and CD8+ T cells in atopic asthma.

Authors:  Sang-Heon Cho; Luminita A Stanciu; Stephen T Holgate; Sebastian L Johnston
Journal:  Am J Respir Crit Care Med       Date:  2004-10-22       Impact factor: 21.405

6.  Inhibition of T cells provides protection against early invasive pneumococcal disease.

Authors:  Kim LeMessurier; Hans Häcker; Elaine Tuomanen; Vanessa Redecke
Journal:  Infect Immun       Date:  2010-09-20       Impact factor: 3.441

7.  The mechanism underlying T cell help for induction of an antigen-specific in vivo humoral immune response to intact Streptococcus pneumoniae is dependent on the type of antigen.

Authors:  Zheng-Qi Wu; Yi Shen; Abdul Q Khan; Ching-Liang Chu; Richard Riese; Harold A Chapman; Osami Kanagawa; Clifford M Snapper
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

8.  Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study.

Authors:  Jonathan M Corne; Clare Marshall; Sandra Smith; Jacquie Schreiber; Gwendolyn Sanderson; Stephen T Holgate; Sebastian L Johnston
Journal:  Lancet       Date:  2002-03-09       Impact factor: 79.321

9.  Evaluation of Th1/Th2 ratio and cytokine production profile during acute exacerbation and convalescence in asthmatic children.

Authors:  M L Kuo; J L Huang; K W Yeh; P S Li; K H Hsieh
Journal:  Ann Allergy Asthma Immunol       Date:  2001-03       Impact factor: 6.347

10.  Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?

Authors:  Marc Lipsitch; Cynthia G Whitney; Elizabeth Zell; Tarja Kaijalainen; Ron Dagan; Richard Malley
Journal:  PLoS Med       Date:  2005-01-25       Impact factor: 11.069

View more
  4 in total

1.  Reduced T-Helper 17 Responses to Streptococcus pneumoniae in Infection-Prone Children Can Be Rescued by Addition of Innate Cytokines.

Authors:  Saleem Basha; Ravinder Kaur; Tim R Mosmann; Michael E Pichichero
Journal:  J Infect Dis       Date:  2017-04-15       Impact factor: 5.226

Review 2.  Risks for infection in patients with asthma (or other atopic conditions): is asthma more than a chronic airway disease?

Authors:  Young J Juhn
Journal:  J Allergy Clin Immunol       Date:  2014-08       Impact factor: 10.793

Review 3.  Respiratory Viral and Bacterial Factors That Influence Early Childhood Asthma.

Authors:  Nontobeko Mthembu; Paul Ikwegbue; Frank Brombacher; Sabelo Hadebe
Journal:  Front Allergy       Date:  2021-07-22

4.  Relationship of Microbial Profile With Airway Immune Response in Eosinophilic or Neutrophilic Inflammation of Asthmatics.

Authors:  Jung Hyun Kim; Hun Soo Chang; Ji Hye Son; Jong Sook Park; Choon Sik Park
Journal:  Allergy Asthma Immunol Res       Date:  2020-05       Impact factor: 5.764

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.